Picture loading failed.

Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-099-1mg 1mg Inquiry
GMP-Bios-ab-099-10mg 10mg Inquiry
GMP-Bios-ab-099-100mg 100mg Inquiry
GMP-Bios-ab-099-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody
INN Name Cergutuzumab
TargetCD66e
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesRoche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna